Re: Conference Call

We agree with your comments. The conference was great, presented by a firm that should have been top-tier since long ago. It needs blind investors not to sense the opportunities presented. The new management is realizing the dreams of Cyto's share holders who have been patient and loyal to the firm's science for four years or more. Besides the outstanding proteomic majic, you will see the sales of each and everyone of the firm's products begin to go up. In the past fifteen days we have observed more and more medical centers ordering Quadramet which, unlike morphine, it does stop the pain but not the patients' respiration. Cyto, we now believe more than ever before, is going to be a member in the elite top-tier, biotech firms.

Please Note: This discussion is open to all site visitors and is not regulated by Prohost. Information posted in the discussion should not be considered to be coming from Prohost Research.

Prohost is an independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm.

Send mail to CompanyWebmaster with questions or comments about this web site.
Copyright © 2001 CompanyLongName
Last modified: October 14, 2003

AVN now 3% away from being #1 in US

Comments

AVN now 3% away from being #1 in US AVANIR Pharmaceuticals price change in past 12 months: 112.9%. Percentage of all stocks that AVANIR Pharmaceuticals outperformed: 97% Some of the reasons for the ongoing success of AVN with the wholly owned subsidiary Xenerex are these: "Using immuno-deficient mice, rather than transgenic mice, Xenerex can produce completely human antibodies faster and cheaper than its competition, big market players like Abgenix Inc., Medarex Inc. and Cambridge Antibody Technology plc, Hansen said. " Bioworld Online, Aug 21, 2000 also: AVN's stem cell research relies on adult stem cells and not from embryos. AVN's stem cell reseach is ok by the Pope and Bush and it is very unique in that they may accomplish what was otherwise thought to be "impossible"! SAN DIEGO, June 6 /PRNewswire/ -- Xenerex Biosciences, a subsidiary of AVANIR Pharmaceuticals (Amex: AVN - news), announced today that it has licensed the rights to a patent for grafting adult human stem cells into severe combined immunodeficient (SCID) mice. The ability to engraft adult human stem cells, which may respond to unique antigens with unique antibodies, broadens the company's technological resources with yet another important option in generating fully human monoclonal antibodies. ``The addition of this exclusive method extends our technology platform with another methodology for generating fully human antibodies to a wide array of infectious diseases and human proteins,'' said J. David Hansen, president and chief operating officer of Xenerex Biosciences. ``With the addition of this unique approach we hope to generate B-cells and antibodies, that are difficult or even impossible to obtain by other methods...." .,.

Prohost Biotechnology Online

The Newsletter of Biotechnology Research and Investment

P R O H O S T O n l i n e
The Newsletter of Biotechnology Insight and Investment

Biotechnology Discussion